Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2015

View Archived Issues

Trevi Therapeutics reports data from phase II/III trial in uremic pruritus

Roche patents mGluR4 PAMs

Gencia and Takeda to discover and develop mitochondrial therapeutic compounds

Isis Pharmaceuticals and AstraZeneca collaboration receives antitrust clearance

Theravance Biopharma and Mylan begin phase III program for revefenacin in COPD

Sanofi reports topline results from phase III LixiLan-L trial

CAT-1004 receives rare pediatric disease designation for Duchenne muscular dystrophy

FDA awards orphan drug designation to MANF for retinal artery occlusion

DNDi and Eisai partner to develop fosravuconazole for eumycetoma

Elevated N-acetylspermidine, a potential biomarker for Snyder Robinson syndrome

Imbruvica NDA submitted to FDA for treatment-naive chronic lymphocytic leukemia

Cancer Research Technology discloses Mps1 inhibitors

World Lymphoma Awareness Day: Chemotherapy-free regimens make progress

Indian CSIR presents PI3Kalpha inhibitors

Riboflavin metabolism abnormalities may induce MADD

Laguna opens phase III RESTORE SR trial of vanoxerine for atrial fibrillation and atrial flutter

FDA accepts IND application for AEB-1102

Achillion discovers complement factor D inhibitors

FORUM and Mitsubishi Tanabe Pharma halt encenicline trials following FDA clinical hold

LIPT2 gene mutations may be associated with lipoic acid biosynthesis defects

Abeta deposition found in subjects with prion disease transmitted by medical treatment

NantPharma licenses Amgen's c-Met inhibitor AMG-337

Erytech seeks EMA approval for Graspa in ALL

Zenyaku Kogyo terminates blisibimod Japanese license agreement with Anthera

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...